Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
RESEARCH TOOLSreports
Holding DNLI?
Track your performance easily
Denali Therapeutics (DNLI) Ownership Overview
9.16% Insiders
33.52% Mutual Funds
0.01% Other Institutional Investors
14.82% ETFs
42.49% Public Companies and Individual Investors
The ownership structure of Denali Therapeutics (DNLI) stock is a mix of institutional, retail, and individual investors. Approximately 48.35% of the company’s stock is owned by Institutional Investors, 9.16% is owned by Insiders, and 42.49% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Jan 08, 2025 | Steve E. Krognes Director | xxxxxxxxxxxxx | $69485 |
| Jan 08, 2025 | Carole Ho Cmo | xxxxxxxxxxxxx | $308291 |
| Jan 08, 2025 | Ryan J. Watts President & Ceo,director | xxxxxxxxxxxxx | $750955 |
| Jan 08, 2025 | Alexander O. Schuth Cofo And Secretary | xxxxxxxxxxxxx | $308291 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2024 | xxxxxxxxxxxxx | $342714 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $15943752 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 10,475,259 | Institution | 7.28% | 196,306,354 | |
| 9,358,249 | Institution | 6.50% | 175,373,586 | |
| 8,797,384 | Institution | 6.11% | 164,862,976 | |
| 6,196,122 | Institution | 4.31% | 116,115,326 | |
| 5,750,882 | Insider | 4.20% | 107,771,529 | |
| 5,978,373 | Institution | 4.15% | 112,034,710 | |
| 3,905,970 | Institution | 2.71% | 73,197,878 | |
| 3,731,695 | Institution | 2.59% | 69,931,964 | |
| 2,455,675 | Insider | 1.71% | 46,019,350 | |
| 2,117,408 | Insider | 1.47% | 39,680,226 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 9,358,249 | Institution | 6.50% | 175,373,586 | |
| 8,797,384 | Institution | 6.11% | 164,862,976 | |
| 5,978,373 | Institution | 4.15% | 112,034,710 | |
| 3,905,970 | Institution | 2.71% | 73,197,878 | |
| 1,638,780 | Institution | 1.14% | 30,710,737 | |
| 1,543,042 | Institution | 1.07% | 28,916,607 | |
| 1,382,410 | Institution | 0.96% | 25,906,363 | |
| 1,372,333 | Institution | 0.95% | 25,717,520 | |
| 1,141,086 | Institution | 0.79% | 21,383,952 | |
| 1,064,733 | Institution | 0.74% | 19,953,096 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,322,295 | Institution | 2.31% | 71,429,343 | |
| 3,292,637 | Institution | 2.29% | 82,315,925 | |
| 2,707,668 | Institution | 1.88% | 67,691,700 | |
| 1,851,644 | Institution | 1.29% | 46,291,100 | |
| 1,576,026 | Institution | 1.10% | 29,534,727 | |
| 1,488,485 | Institution | 1.03% | 37,212,125 | |
| 793,998 | Institution | 0.55% | 17,070,957 | |
| 658,708 | Institution | 0.46% | 14,162,222 | |
| 600,962 | Institution | 0.42% | 11,262,028 | |
| 585,155 | Institution | 0.41% | 14,628,875 |
FAQ
Who Owns Denali Therapeutics (DNLI)?
According to the latest TipRanks data, approximately 0.01% of the company's stock is held by institutional investors, 9.16% is held by insiders, and 42.49% is held by retail investors.
What percentage of Denali Therapeutics (DNLI) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.01% of Denali Therapeutics (DNLI) stock is held by institutional investors.
What percentage of Denali Therapeutics (DNLI) stock is held by retail investors?
According to the latest TipRanks data, approximately 42.49% of Denali Therapeutics (DNLI) stock is held by retail investors.
Who owns the most shares of Denali Therapeutics (DNLI)?
Vanguard owns the most shares of Denali Therapeutics (DNLI).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.